The use of RWD to assess safety outcomes in the US and EU
As regulatory expectations for drug and device safety monitoring evolve, real-world data (RWD) offers a scalable, cost-effective solution for generating robust evidence. This whitepaper explores the strengths and limitations of claims and EHR data in the US and EU and provides a stepwise framework for selecting fit-for-purpose datasets that are essential for meeting evolving regulatory expectations.